Idarubicin
- Generic Name
- Idarubicin
- Brand Names
- Idamycin
- Drug Type
- Small Molecule
- Chemical Formula
- C26H27NO9
- CAS Number
- 58957-92-9
- Unique Ingredient Identifier
- ZRP63D75JW
- Background
An orally administered anthracycline antineoplastic. The compound has shown activity against breast cancer, lymphomas and leukemias, together with the potential for reduced cardiac toxicity.
- Indication
For the treatment of acute myeloid leukemia (AML) in adults. This includes French-American-British (FAB) classifications M1 through M7.
- Associated Conditions
- Acute Myeloid Leukemia
Treateament of Newly Diagnosed Acute Monocytic Leukemia in Children
- Conditions
- Pediatric AMLLeukemia, Monocytic, Acute
- Interventions
- First Posted Date
- 2022-04-06
- Last Posted Date
- 2023-07-27
- Target Recruit Count
- 43
- Registration Number
- NCT05313958
- Locations
- 🇨🇳
Guangzhou First People's Hospital, Guangzhou, Guangdong, China
🇨🇳The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China
🇨🇳Maternal and Child Health Hospital of Foshan, Foshan, Guangdong, China
Lipiodol-TACE With Idarubicin for Hepatocellular Carcinoma
- Conditions
- Hepatocellular Carcinoma
- Interventions
- First Posted Date
- 2022-03-15
- Last Posted Date
- 2022-12-29
- Lead Sponsor
- Zhongda Hospital
- Target Recruit Count
- 216
- Registration Number
- NCT05280444
- Locations
- 🇨🇳
Zhongda Hospital, Southeast University, Nanjing, Jiangsu, China
Venetoclax + Decitabine vs. "7+3" Induction Chemotherapy in Young AML
- Conditions
- AML, AdultChemotherapy Effect
- Interventions
- First Posted Date
- 2022-01-05
- Last Posted Date
- 2024-10-03
- Lead Sponsor
- Chen Suning
- Target Recruit Count
- 188
- Registration Number
- NCT05177731
- Locations
- 🇨🇳
The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, Suzhou, Jiangsu, China
Idarubicin vs. Epirubicin TACE in the Treatment of Hepatocellular Carcinoma
- Conditions
- Hepatocellular Carcinoma
- Interventions
- First Posted Date
- 2021-09-22
- Last Posted Date
- 2021-09-22
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 186
- Registration Number
- NCT05053386
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
Bcl-2 Inhibitors Combined With Azacytidine and Chemotherapy in Elderly Patients With Previously Untreated AML
- Conditions
- Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2021-09-22
- Last Posted Date
- 2022-04-26
- Lead Sponsor
- LanZhou University
- Target Recruit Count
- 30
- Registration Number
- NCT05053425
- Locations
- 🇨🇳
Long Zhao, Lanzhou, Gansu, China
Venetoclax + Azacitidine vs. Induction Chemotherapy in AML
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Drug: Liposomal daunorubicin and cytarabine
- First Posted Date
- 2021-03-17
- Last Posted Date
- 2025-05-11
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 172
- Registration Number
- NCT04801797
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸University of California - Davis, Sacramento, California, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Study of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Patients With TP53 Mutant Acute Myeloid Leukemia That Have Not Been Treated
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Drug: Steroidal Eye Drops
- First Posted Date
- 2021-03-03
- Last Posted Date
- 2025-02-05
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 258
- Registration Number
- NCT04778397
- Locations
- 🇦🇺
Fiona Stanley Hospital, Murdoch, Western Australia, Australia
🇦🇺Royal Adelaide Hospital, Adelaide, South Australia, Australia
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
Risk-adapted Therapy for Primary Acute Myeloid Leukemia
- Conditions
- Leukemia, Myeloid, Acute
- Interventions
- Procedure: Allogeneic matched or unrelated donor transplant.Procedure: Autologous peripheral blood stem cell transplantProcedure: Measurable residual disease
- First Posted Date
- 2020-12-29
- Last Posted Date
- 2023-06-27
- Target Recruit Count
- 1034
- Registration Number
- NCT04687098
- Locations
- 🇪🇸
ICO Hospital Universitari de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain
🇪🇸Hospital Universitari Son Espases, Palma de Mallorca, Mallorca, Spain
🇪🇸Hospital Universitari Son Llatzer, Palma de Mallorca, Mallorca, Spain
CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia
- Conditions
- Recurrent Chronic Myelomonocytic LeukemiaRecurrent Myelodysplastic SyndromeRefractory Acute Myeloid LeukemiaRefractory Chronic Myelomonocytic LeukemiaRefractory Mixed Phenotype Acute LeukemiaRecurrent Acute Myeloid LeukemiaRefractory Myelodysplastic SyndromeRefractory Acute Leukemia of Ambiguous LineageRefractory Acute Undifferentiated Leukemia
- Interventions
- Procedure: Hematopoietic Cell TransplantationRadiation: Total-Body IrradiationProcedure: Multigated Acquisition ScanProcedure: EchocardiographyProcedure: X-Ray ImagingProcedure: Bone Marrow BiopsyProcedure: Bone Marrow AspirationProcedure: Biospecimen Collection
- First Posted Date
- 2020-05-05
- Last Posted Date
- 2025-02-20
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 120
- Registration Number
- NCT04375631
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Comparing the Consolidation Regimens of IDA With Intermediate-dose Cytarabine Versus Intermediate-dose Cytarabine Alone for Elderly AML Patients
- First Posted Date
- 2020-01-03
- Last Posted Date
- 2020-01-03
- Lead Sponsor
- Fujian Medical University
- Target Recruit Count
- 320
- Registration Number
- NCT04216771
- Locations
- 🇨🇳
Fujian Medical University Union Hospital, Fuzhou, Fujian, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.